Global biosimilar lymphocyte modulator Market

Immuno-Oncology Drugs Market Definition

The immuno-oncology drugs market consists of sales of immuno-oncology drugs by entities (organizations, sole traders and partnerships) that are used for the treatment of cancer. Immuno-oncology is the artificial stimulation of the immune system to treat cancer, improving the immune system's ability to fight the disease. The market consists of revenue generated by the companies’ manufacturing immuno-oncology drugs by the sales of these products.

Cellular immunotherapy refers to a sort of immunotherapy in which a patient receives T cells, an immune cell, to aid the body in fighting diseases like cancer. It is a cutting-edge kind of treatment that uses the body's immune system to combat cancer. The main therapies of cellular immunotherapy are tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy that involves extracting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro, and then infusing them back into patients to treat them. The various primary indications include b-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin lymphoma, and others, and are used for the treatment of prostate cancer, breast cancer, skin cancer, ovarian cancer, brain tumours, lung cancer, and others. The cellular immunotherapy market research report is one of a series of new reports from The Business Research Company that provides cellular immunotherapy market statistics, including cellular immunotherapy industry global market size, regional shares, competitors with a cellular immunotherapy market share, detailed cellular immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the cellular immunotherapy industry. This cellular immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cellular immunotherapy market grew from $4.3 billion in 2022 to $5.03 billion in 2023 at a compound annual growth rate (CAGR) of 17.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cellular immunotherapy market is expected to grow from $8.59 billion in 2027 at a CAGR of 14.3%. Increasing research and successful clinical trials in cellular immunotherapy are expected to drive the growth of the cellular immunotherapy market over the forecast period. Companies are focusing on developing new cellular immunotherapies for treating different diseases. For instance, in June 2022, according to a report published by the Cancer Research Institute, a US-based nonprofit organization devoted solely to developing immunotherapy for the prevention, treatment, and eventual eradication of all cancers, in the worldwide immuno-oncology pipeline as of April 2022, there were 2,756 active cell therapy drugs, up 36% from the landscape analysis of 2021 that revealed 2,031 such agents but also a slight slowdown from the 43% growth in the previous year. The rapid growth in the development of cellular immunotherapy in clinical and preclinical stages in 2020 as compared to that in 2019 is projected to expand the landscape of cellular immunotherapy. Subsequently, generating higher revenues for the cellular immunotherapy market. The high cost of cellular immunotherapies is anticipated to hinder cellular immunotherapy’s market growth. CAR-T therapy is a type of cellular immunotherapy and only two have been approved in the USA. The price of Yescarta and Kymriah is more than $350,000 per treatment in the USA, which is highly unaffordable for a majority of the patients, especially with low income. The high cost of cellular immunotherapies discourages patients to opt for this drug, thereby, impacting the demand and the market negatively. Companies in the cellular immunotherapy market are focusing on developing off-the-shelf allogeneic therapies for new and improved cancer treatment. Off-the-shelf allogeneic therapies are produced from the cells of donors instead of the patient's cells, as in the case of autologous therapy. Their non-customized nature provides advantages such as cost-effectiveness, large scale, fast production, and quality control. For instance, in May 2022, Novartis AG, a Switzerland-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of drugs, announced that after two or more lines of systemic therapy, the US Food and Drug Administration (FDA) has given expedited approval for Kymriah® (tisagenlecleucel) to treat adult patients with relapsed or refractory (r/r) follicular lymphoma (FL). In addition, Acepodia, a US-based next-generation cell immuno-technology company, will begin a phase 1 clinical trial in August 2020 to evaluate ACE1702, an allogeneic, off-the-shelf NK cell therapy, for the treatment of solid tumors. In April 2020, resTORbio, Inc., a US-based biopharmaceutical company specialising in the development and commercialization of drugs used for the treatment of aging-related diseases, merged with Adicet Bio, Inc., a biopharmaceutical company, for an undisclosed amount. Both the companies continue their operations as ‘Adicet Bio’. This merger is expected to help the companies advance allogeneic gamma-delta CAR-T cell therapy technology. Adicet Bio, Inc. is a US-based company specialising in the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications. Major players in the cellular immunotherapy market are Novartis AG, Gilead Sciences Inc. (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC., JW CreaGene Co. Ltd., Green Cross Corp. (GC Pharma), AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., and Roche. The regions covered in the global cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the global cellular immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cellular immunotherapy market includes revenues earned by entities by inventing, developing, administering, and understanding engineered immune effector cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply c either further along the supply chain or as part of other products. The global cellular immunotherapy market is segmented - 1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, and Natural Killer (NK) Cell Therapy 2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin Lymphoma, Other Primary Indications 3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumour, Lung Cancer, Other Applications

A biosimilar refers to a medication that closely resembles a biologic medication in both structure and function. A biologic drug, however, is a treatment created using a biological system, such as yeast, bacteria, or animal cells. A biological product is considered "biosimilar" if it is extremely similar to and bears no discernible clinical differences from an FDA-approved reference product already in use. The main therapy types are oral biologics and biosimilar lymphocyte modulators, interleukin inhibitors, and tumour necrosis factor-alpha inhibitors. Interleukin inhibitors are immunosuppressive drugs that stop interleukins from working. Interleukins are a family of cytokines produced by lymphocytes, monocytes, macrophages, and a few other cells. They play an important role in immune system regulation. The various diseases treated include asthma, Crohn’s disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis, and others, by vaccines, proteins and peptides, monoclonal antibodies, and others. The drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The oral biologics market research report is one of a series of new reports from The Business Research Company that provides oral biologics market statistics, including oral biologics industry global market size, regional shares, competitors with an oral biologics market share, detailed oral biologics market segments, market trends and opportunities, and any further data you may need to thrive in the oral biologics industry. This oral biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global oral biologics & biosimilar drugs market grew from $4.91 billion in 2022 to $5.94 billion in 2023 at a compound annual growth rate (CAGR) of 21.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oral biologics & biosimilar drugs market is expected to grow from $11.77 billion in 2027 at a CAGR of 18.6%. The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the oral biologics and biosimilar market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases, and biologics are increasingly used to treat these chronic diseases. Biologics activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biologics and biosimilars, thus driving the biologics and biosimilar market. Stringent regulations imposed on the approval of biosimilar are anticipated to hinder the growth of oral biologics and the biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biologics and biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug for biologics whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. For instance, according to 2021 Biosimilars Trend Report, in year 2020, the FDA approved 3 biosimilars. The COVID-19 epidemic and the ensuing closure most likely slowed the approval of biosimilars. In contrast, the FDA authorised 10 biosimilars in 2019, bringing the US total to 26. The robust government policies for approval of these drugs impact the manufacturers in oral biologics and biosimilar markets. The latest trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin. This is also promoting competition among various biosimilar manufacturers. For instance, in August 2020, Biocon Biologics India Ltd., an India-based fully integrated global biosimilars organization, in partnership with Mylan, a US-based biosimilar company, has launched Semglee, insulin glargine injection in the U.S. Major players in the oral biologics & biosimilar drugs market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca PLC., Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan PLC., Emisphere Technologies, Enteris BioPharma, Chiasma, Allena Pharmaceuticals, Gelgen, Ganlee, 3sbio, Innovent, Retractable Technologies, Inc., Changchun High Tech, Dong Bao, CP Guojian, GlaxoSmithKline PLC., Concord Biotech, Aurobindo Pharma Ltd., H. Lundbeck A/S, Sanofi-Aventis and Roche. North America was the largest region in the oral biologics and biosimilar drugs market in 2022. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the global oral biologics and biosimilar drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The oral biologics and biosimilar market consists of sales of therapeutic proteins, cystic fibrosis, somatic cells, and allergenics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global oral biologics & biosimilar drugs market is segmented - 1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors 2) By Disease: Asthma, Crohn'S Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis, and Others 3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, and Other Molecule Types 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Colorectal cancer (CRC) or bowel cancer, is a type of cancer affecting the large intestine and the rectum. Depending on where they begin, they are also known as colon tumours or rectal cancer. The main types of colorectal cancer drugs are vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, and programmed cell death protein 1/PD1 ligand 1 (PD1/PDL1) inhibitors, BRAF or MEK inhibitors, tyrosine kinase (TKI) inhibitors, and immunomodulators. Vascular endothelial growth factors (VEGF) are drugs that block VEGF and VEGFR activity. The various classes of drugs include immunotherapy, chemotherapy, and others that are distributed by hospitals pharmacies, retail pharmacies, and others. The colorectal cancer drugs market research report is one of a series of new reports from The Business Research Company that provides colorectal cancer drugs market statistics, including colorectal cancer drugs industry global market size, regional shares, competitors with a colorectal cancer drugs market share, detailed colorectal cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the colorectal cancer drugs industry. This colorectal cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global colorectal cancer drugs market size will grow from $13.65 billion in 2022 to $14.21 billion in 2023 at a compound annual growth rate (CAGR) of 4.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global colorectal cancer drugs market size is expected to grow to $16.22 billion in 2027 at a CAGR of 3.3%. The number of cases of colorectal cancer worldwide has been increasing. For instance, in March 2020, according to research published in ACS Publications, a US-based scientific journal, based on data from the National Center for Health Statistics, a total of 147,950 people would be diagnosed with CRC, and 53,200 would pass away from it. 17,930 of these cases and fatalities will be in people under the age of 50. The number of diagnosed incident cases of colorectal cancer is expected to increase by 27.3% to 672,400 cases by 2037. The reason for this increase can be attributed to factors such as a low-fiber diet, obesity, and consumption of alcohol and tobacco, among others. The increase in the number of colorectal cancer cases will add to the overall size of the global colorectal cancer drug market. The increasing use of biologics and targeted therapies restrains the bladder cancer drugs market. Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs which reduces the body’s immune power. Targeted therapies block the growth and spreading of colorectal cancer even in stage IV where chemical drugs are ineffective. For example, some targeted therapies that have been approved to treat colorectal cancer include bevacizumab, cetuximab, and panitumumab. The advantages of biological drugs and targeted therapies over conventional chemical drugs might negatively influence the market. Targeted therapies have already begun to extend the lifespan of metastatic Colorectal cancer patients compared with chemotherapy-only therapy. Target therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells while sparing the toxicity to off-target cells. Opdivo and Keytruda are examples of targeted therapies. The colorectal cancer industry is governed by a regulatory framework laid down by agencies such as the US Food and Administration Agency (FDA), the European Medicines Agency (EMA), the American Society of Clinical Oncology (ASCO), and others. For instance, the FDA's recommendation for the colorectal cancer drugs industry in the form of guidelines is mentioned within the CFR's (Code for Federal Regulations) title number 21 under part 312, which contains sub-parts from A to me. The sub-part E deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening illnesses such as colorectal cancer. It also includes guidelines for the monitoring and evaluation of clinical trials of colorectal cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. In November 2020, Merck & Co., Inc., a US-based research-oriented biopharmaceutical company, acquired VelosBio, Inc., for an amount of $2.75 billion. Through this acquisition, Merck will strengthen its oncology drug pipeline with VLS-101 for the treatment of patients with hematologic malignancies and solid tumours and its research capabilities in the field of cancer research. VelosBio, Inc. is a US-based clinical-stage biopharmaceutical company specialising in the development of brand-new antibody-drug conjugates ("ADCs") to treat solid tumours and hemological malignancies. Major players in the colorectal cancer drugs market are Merck & Co. Inc., Roche, Sanofi, Amgen, Pfizer Inc., Abbott Laboratories, Taiho Pharma, Novartis, GlaxoSmithKline, Onyx, TAKEDA PHARMACEUTICALS, Bristol-Myers Squib, Sumitomo Dainippon Pharma, Array BioPharma, Eli Lilly, RANDOX LABORATORIES, Suzhou Zelgen Biopharmaceuticals, Beckman Coulter Inc., Regeneron, EDP Biotech, Genomic Tree, Metabiomics Corporation, SIEMENS HEALTHCARE, Suzhou Zelgen Biopharmaceuticals, Sumitomo Dainippon Pharma and EPIGENOMICS. North America was the largest region in the colorectal cancer drugs market in 2022. The Middle East is expected to be the fastest-growing region in the global colorectal cancer drugs market during the forecast period. The regions covered in the global colorectal cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the colorectal cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The colorectal cancer drug market consists of sales of avastin, bevacizumab, and camptosar. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global colorectal cancer drugs market is segmented - 1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators 2) By Distribution Channels: Hospitals Pharmacies, Retail Pharmacies, Other Distribution Channels 3) By Class: Immunotherapy, Chemotherapy, Other Classes

Multi sclerosis drug refers to medications that are designed to stop the progression of disability and disease relapses. These medications are referred to as "disease-modifying treatments." These drugs target a protein on the surface of immune cells and reduce the number of white blood cells to help prevent MS relapses. The white blood cells' propensity for nerve injury may be reduced by this impact. The main drug class of multiple sclerosis drugs is immunomodulators, immunosuppressants, interferons, and others. Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The various routes of administration include oral drugs and parenteral drugs that are distributed through hospital pharmacies, retail pharmacies, and online stores. The multiple sclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides multiple sclerosis drugs market statistics, including multiple sclerosis drugs industry global market size, regional shares, competitors with a multiple sclerosis drugs market share, detailed multiple sclerosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the multiple sclerosis drugs industry. This multiple sclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global multiple sclerosis drugs market grew from $26.29 billion in 2022 to $27.92 billion in 2023 at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The multiple sclerosis drugs market is expected to grow from $37.67 billion in 2027 at a CAGR of 7.8%. The growth of the multiple sclerosis drugs market is aided by the support from the government as well as non-government organizations. The government and non-government organizations fund several schemes and programs to offer their support to enhance the quality of life of people affected with multiple sclerosis (MS). For instance, the government of Alberta in partnership with the Department of Economic Development, Trade, and Tourism in Canada invested $ 1 million towards the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) to support the research and innovations to enhance understanding and treatment for MS disease. CanProCo is an initiative to consolidate the efforts of nearly 50 MS researchers from various disciplines across Canada. The initiative was further funded by the Canada Brain Research, Biogen Canada, and the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada) to raise a total of $10 million. Appropriate financial support from the government and non-government organizations boosts the growth of the multiple sclerosis drugs market. The high cost of drugs to treat multiple sclerosis (MS) restricts the growth of the multiple sclerosis drugs market. MS is a cureless disease with high chances of a disability and requires lifelong treatment. Despite the heavy competition among the drug companies, the cost of MS drugs is high, increasing the overall cost of treatment. The companies operating in the multiple sclerosis drugs market often have to work towards reducing the cost of these drugs to justify their cost-effectiveness to their consumers. As reported by Institute for Clinical and Economic Review (ICER), MS drugs cost roughly between $63,000 and $104,000 annually. For instance, after receiving criticism from the National Multiple Sclerosis Society on the high price of Vumerity, a drug to treat relapse MS, Biogen and Alkermes had to reduce the prices of the drug to $88,000 per year to make it affordable to the patients. The high cost of drugs, which are required lifelong negatively affects the growth of the multiple sclerosis drugs market. The companies are rapidly intensifying their efforts to focus on new product launches to cater to the rising demands for MS drugs. Multiple sclerosis requires lifelong treatment, which increases the overall cost of treating a patient. To provide better and more effective treatment companies in the multiple sclerosis market are developing drugs specific to the treatment of multiple sclerosis. Following the trend, FDA approved Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribine) for the treatment of relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS). Both the drugs were launched as easy-to-consume oral drugs. Bristol-Myers Squibb, a pharmaceutical company based in the United States, paid $74 billion for Celgene.Through the acquisition, Bristol-Myers Squibb aims to increase its product portfolio by utilising the existing products of Celgene along with its technical and pipeline support. Ozanimod is one of Celgene’s pipeline drugs for the treatment of relapsing multiple sclerosis. The drug is currently in phase III clinical trials to be approved by the FDA. Celgene is a pharmaceutical company based in the United States that develops and markets medicines for cancer and inflammatory diseases such as multiple sclerosis. Major players in the multiple sclerosis drugs market are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer Inc., and Merck & Co. Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, Acorda Therapeutics Inc., Actelion Pharmaceutical, EMD Serono, AbbVie Inc., Betaseron, CinnoVex, Extavia, Rebif, and Tysabr. North America was the largest region in the global multiple sclerosis drug market in 2022. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the global multiple sclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the multiple sclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The multiple sclerosis drug market consists of sales of lemtrada, novantrone, ocrevus, and tysabri. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global multiple sclerosis drugs market is segmented - 1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes 2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores 3) By Route Of Administration: Oral Drugs, Parenteral Drugs

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biologic cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy. The main drug types of oncology biosimilars are monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer, and the various distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies. The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with an oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global oncology biosimilars market grew from $4.19 billion in 2022 to $5.38 billion in 2023 at a compound annual growth rate (CAGR) of 28.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oncology biosimilars market is expected to grow from $12.83 billion in 2027 at a CAGR of 24.3%. The expiration of the patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms that induce the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offer the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars. The lack of awareness of biosimilars among primary care physicians (PCPs) and specialists limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, a lack of detailed awareness of the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns including the safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the oncology biosimilars market. The pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting the growth potential of the rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody in the US and Canada. Coherus plan to build a leading immuno-oncology franchise using cash from its commercial biosimilar business. Also, in 2019, Biocon, India’s largest biotechnology company invested to acquire some assets of Pfizer Healthcare to set up an R&D facility to boost biosimilar development. Major players in the oncology biosimilars market are Bitcoin, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen, Hospira, F Hoffmann-La Roche, Baxter, Sanofi, Mylan, and F Hoffmann-La Roche. North America was the largest region in the global oncology biosimilars market in 2022. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the global oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global oncology biosimilars market is segmented - 1) By Drug Type: Monoclonal Antibodies, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF) 2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types 3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Immuno-oncology drugs refer to a therapy or cancer treatment that employs drugs to either boost or suppress the immune system in order to aid the body's defences against cancer, infection, and other disorders. It makes use of chemicals produced by the body or in a lab to strengthen the immune system and assist the body in locating and eliminating cancer cells. The main types of immuno-oncology drugs are monoclonal antibodies, immune checkpoint inhibitors, immune system modulators, cancer vaccines, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different therapeutic applications include melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer, and others and involve various sectors such as hospitals, clinics, ambulatory surgical centers, and cancer research institutes. The immuno-oncology drugs market research report is one of a series of new reports from The Business Research Company that provides immuno-oncology drugs market statistics, including industry global market size, regional shares, competitors with an immuno-oncology drugs market share, detailed immuno-oncology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the immuno-oncology drugs industry. This immuno-oncology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global immuno-oncology drugs market grew from $70.59 billion in 2022 to $81.46 billion in 2023 at a compound annual growth rate (CAGR) of 15.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The immuno-oncology drugs market is expected to grow from $136.15 billion in 2027 at a CAGR of 13.7%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the immuno-oncology drug market. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the immune-oncology drugs market over the coming years. The high cost of immuno-oncology therapies is a key factor hampering the growth of the market. The immunotherapy drugs cost more than other cancer drugs, and people who need immunotherapy for cancer, are often not able to afford it. High costs associated with drugs are a major issue faced by patients across the globe. The pressure to contain costs and demonstrate value is widespread. In less wealthy countries, the lack of cost-effective drugs has influenced the health conditions of the population and led to a low average life expectancy. Immunotherapy often costs an average annual price of more than $100,000 per patient, and if the value of medical assistance is included, the price would reach $850,000 per patient. Therefore, the high cost of immuno-oncology therapies is expected to hinder the growth of the immuno-oncology drug market. Companies in the immuno-oncology drug market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive immuno-oncology drug market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over the past few years. For instance, in September 2020, AbbVie, Inc., a US based biopharmaceutical company specialising in drug discovery, research, and development, announced its research collaboration with I-Mab Biopharma Co. Ltd., a China based biopharmaceutical company pioneering in the discovery, development, and commercialization of biological drugs for immunology. Through this collaboration, both companies focus on the development of Lemzoparlimab (also known as TJC4), a cutting-edge anti-CD47 monoclonal antibody that I-Mab internally discovered and developed for the treatment of various cancers. The agreement covers its development and commercialization. The two partners may also decide to collaborate on further breakthrough cures in the future. In December 2021, Sanofi S.A., a France-based biopharmaceutical and healthcare company, acquired Amunix Pharmaceuticals, Inc., for an amount of $1 billion. Through this acquisition, Sanofi increases its capabilities in the development of innovative medicines for cancer patients, in research and drug discovery of immune-oncology therapeutic candidates, brings these potentially superior and safer treatment candidates to patients by utilising its expertise and working as a centre of excellence together, and increases its oncology pipeline. Amunix Pharmaceuticals, Inc., is a US-based biopharmaceutical company specialising in the discovery and development of novel immuno-oncology drugs. Major players in the immuno-oncology drugs market are Amgen Inc., AstraZeneca PLC., Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, and AbbVie Inc. North America was the largest region in the immuno-oncology drugs market in 2022. The regions covered in the global immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the immuno-oncology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The immune-oncology drug market consists of sales of bevacizumab, alectinib, ibrutinib, imatinib, and palbociclib. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global immuno-oncology drugs market is segmented - 1) By Type: Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Other Types 2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Other Therapeutic Applications 3) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Cancer Research Institutes

Silicon photonics refers to a new technology in which data is transferred among computer chips by optical rays. Optical rays can carry huge data in less time than electrical conductors. Semiconductor-grade silicon is used in silicon photonics for the integration of active and passive integrated photonic circuits with electronic components. Silicon photonics is the new study and application of photonic systems for generating, processing, manipulating, and also using for faster data transfer both between and within microchips. The main product types of silicon photonics are transceivers, variable optical attenuators, switches, cables, and sensors. The transceivers in silicon photonics are used to gain high-bandwidth, software-configurable access to computing and storage. When compared to traditional electronics, this eliminates networking bottlenecks that result in stranded computation capacity and allows for considerably faster data transport over larger distances. The components of silicon photonics include a laser, modulator, photodetector, filter, and wave guide. Various applications of silicon photonics include data centres and high-performance computing; telecommunication; military, defence and aerospace; medical and life science; and others. The Silicon Photonics market research report is one of a series of new reports from The Business Research Company that provides Silicon Photonics market statistics, including Silicon Photonics industry global market size, regional shares, competitors with a Silicon Photonics market share, detailed Silicon Photonics market segments, market trends and opportunities, and any further data you may need to thrive in the Silicon Photonics industry. This Silicon Photonics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry. The global silicon photonics market size grew from $1.51 billion in 2022 to $1.91 billion in 2023 at a compound annual growth rate (CAGR) of 26.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The silicon photonics market size is expected to grow to $4.68 billion in 2027 at a CAGR of 25.1%. Growing demand for high-speed broadband services is expected to propel the growth of the silicon photonics market. High-speed broadband services are widely used in mobiles and laptops, smart home applications, online education, virtual private LAN services, interactive gaming, and others. Silicon photonics technology uses a sub-micrometer SOI (silicon on insulator) platform, which is widespread in the field of fibre optic interconnects, which helps for better data transmission both between and within microchips. According to the Organisation for Economic Co-operation and Development, Austria, Belgium, Chile, Ireland, Israel, and the United Kingdom all increased their fibre connections by more than 50% in 2020. Additionally, during the COVID-19 pandemic in 2020, in 38 OECD (Organisation for Economic Co-operation and Development) countries, the number of new broadband connections stood at a massive 21.15 million. Therefore, the growing demand for high-speed broadband services is driving the growth of the silicon photonics market. Technological advancements are a key trend gaining popularity in the silicon photonics market, with companies launching new products with advanced technologies such as high power and optical filtering tolerance. For instance, in September 2021, NeoPhotonics Corp, a US-based designer and manufacturer of silicon photonics, launched a CFP2-DCO module with 0dBm output power for ROADM-based metro, regional, and long-haul networks. This product has a transmission speed of 400 Gbps over a range of 1,500 km. This system contains an ultra-pure Nano tunable laser, as well as a Class 40 coherent receiver and coherent driver modulator that can transmit data at up to 67 Gbaud. This allows for longer-distance transmission while also improving the receiver optical signal-to-noise ratio (rOSNR). In November 2021, Lumentum, a US-based manufacturer of innovative optical and photonic products, acquired NeoPhotonics for a deal amount of $918 million. Through this acquisition, Lumentum is expected to expand its opportunity in the optical components market, particularly for cloud and telecom network infrastructure. NeoPhotonics is a US-based designer and manufacturer of silicon photonics and hybrid photonic integrated circuit (PIC)-based lasers, subsystems, and modules for high-speed communications. Major players in the silicon photonics market are Acacia Communications, Broadcom Ltd., Cisco Systems, MACOM Technology, Finisar Corporation, Globalfoundries Inc., IBM Corporation, Ii-Vi Incorporated, Inphi, Intel Corporation, Juniper Networks, Mellanox Technologies, NeoPhotonics, Ranovus, Rockley Photonics Ltd., Sicoya, Luxtera, and Reflex Photonics Inc. Asia-Pacific was the largest region in the silicon photonics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the silicon photonics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the Silicon Photonics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The silicon photonics market consists of sales of switches, transceivers, cables, variable optical attenuators, and other silicon photonics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global silicon photonics market is segmented - 1) By Product: Transceivers, Variable Optical Attenuators, Switches, Cables, Sensors 2) By Component: Laser, Modulator, Photodetector, Filter, Wave Guide 3) By Application: Data Centers And High-Performance Computing, Telecommunication, Military, Defense And Aerospace, Medical And Life Science, Other Applications